Literature DB >> 14512528

Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Z Q Xiang1, G P Gao, A Reyes-Sandoval, Y Li, J M Wilson, H C J Ertl.   

Abstract

Adenovirus vectors with E1 deleted of the human serotype 5 (AdHu5) and the chimpanzee serotype 68 (AdC68) expressing the glycoprotein of the Evelyn Rokiniki Abelseth strain of rabies virus were tested upon oral application for induction of systemic and mucosal transgene product-specific antibody responses in mice. Both vectors induced systemic and mucosal antibodies to rabies virus, including virus-neutralizing antibodies and protection against a severe intracerebral challenge with a mouse-adapted strain of rabies virus. Pre-existing immunity of AdHu5 virus, which dampens induction of transgene product-specific immunity elicited by AdHu5 vectors given systemically did not impair the response induced by oral vaccination. Oral priming-boosting regimens with either heterologous or homologous adenoviral vectors used sequentially increased both mucosal and systemic antibody titers to rabies virus [corrected]

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512528      PMCID: PMC224991          DOI: 10.1128/jvi.77.20.10780-10789.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells.

Authors:  L Zhong; A Granelli-Piperno; Y Choi; R M Steinman
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

2.  Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.

Authors:  I M Belyakov; B Moss; W Strober; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

Authors:  Z Q Xiang; Y Yang; J M Wilson; H C Ertl
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

4.  Laboratoty techniques in rabies: tissue culture methods.

Authors:  T J Wiktor
Journal:  Monogr Ser World Health Organ       Date:  1973

5.  The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1.

Authors:  Z Papp; L A Babiuk; M E Baca-Estrada
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

6.  Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver.

Authors:  S Kuriyama; K Tominaga; M Kikukawa; T Nakatani; H Tsujinoue; M Yamazaki; S Nagao; Y Toyokawa; A Mitoro; H Fukui
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  Comparison studies on potency tests for rabies vaccines.

Authors:  T J Wiktor; P Atanasiu; M Bahmanyar; K Boegel; J H Cox; A M Diaz; E A Fitzgerald; E Kuwert; R Netter; M Selimov; G Turner; G van Steenis
Journal:  Dev Biol Stand       Date:  1978

8.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  Immune effector mechanisms required for protection to rabies virus.

Authors:  Z Q Xiang; B B Knowles; J W McCarrick; H C Ertl
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

10.  Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

Authors:  Z Q Xiang; S Spitalnik; M Tran; W H Wunner; J Cheng; H C Ertl
Journal:  Virology       Date:  1994-02-15       Impact factor: 3.616

View more
  65 in total

1.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

2.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

3.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

5.  Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.

Authors:  S W Lin; A S Cun; K Harris-McCoy; H C Ertl
Journal:  Vaccine       Date:  2006-12-06       Impact factor: 3.641

6.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.

Authors:  Dongming Zhou; Te-Lang Wu; Marcio O Lasaro; Brian P Latimer; Elizabeth M Parzych; Ang Bian; Yan Li; Hua Li; Jan Erikson; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 7.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

8.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 10.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.